Sunshine Biopharma approves warrant provisions
- Approved by Dr. Steve N. Slilaty, 89.5% voting power
- Series D Warrants exercisable at $0.66 per share
- Warrant stockholder approval effective 20 days after mailing
SBFM
Sunshine Biopharma Inc. SEC filings
Every EDGAR filing for Sunshine Biopharma Inc. (SBFM), newest first, with AI summaries and stories.
- Ticker
- SBFM
- CIK
- 1402328
- Sector
- Biotech and pharma
- Latest filing
- 4d
Next: earnings expected ~Oct 6 ยท 10-Q expected ~Nov 13 (deadline Nov 16)
Filings
PRE 14CSunshine Biopharma Inc.SBFMWLIVE 8-KSunshine Biopharma Inc.SBFMWLIVE Sunshine Biopharma approves stock issuance
- Dr. Steve N. Slilaty approved issuing >20% of shares
- Shares issued at discount to Nasdaq minimum price
- Adjustments to Series D Warrants allowed
SCHEDULE 13GSunshine Biopharma Inc.SBFMWLIVE Sunshine Biopharma Inc. 13G filing by BJI Financial Group
- BJI Financial Group owns 6.0% of Sunshine Biopharma Inc.
- Shares beneficially owned: 909,900
- Filing date: 2026-10-14
BJI Financial Group, filed by
SCHEDULE 13GSunshine Biopharma Inc.SBFMWLIVE Sunshine Biopharma Inc. 9.9% held by CVI Investments
- CVI Investments, Inc. holds 1,588,266 shares
- 9.9% of total shares
- Heights Capital Management, Inc. is investment manager
CVI Investments, Inc., filed by
8-KSunshine Biopharma Inc.SBFMWLIVE Sunshine Biopharma Inc. raises $6M
- Closed on 2026-10-09
- Raised $6M before fees
- Common Units at $0.55 each
424B4Sunshine Biopharma Inc.SBFMWLIVE Sunshine Biopharma Inc. offers $6M in units.
- Up to 10,509,082 common units offered.
- Each unit includes 1 share and 2 Series D warrants.
- Up to 400,000 pre-funded units offered.
EFFECTSunshine Biopharma Inc.SBFMWLIVE Sunshine Biopharma Inc. files S-1 form
- Filed on October 7, 2026
- Form S-1 submitted
- CIK 0001402328
SCHEDULE 13G/ASunshine Biopharma Inc.SBFMWLIVE Sunshine Biopharma Inc. reports 4.9% stake
- Alta Partners LLC owns 200,000 shares
- 4.9% of total shares
- Filing date: 2026-10-05
Alta Partners LLC
S-1Sunshine Biopharma Inc.SBFMWLIVE Sunshine Biopharma files S-1
- Filed S-1 on 2026-10-02
- Up to $7M offering
- Common Units with 2 Series D Warrants
DEF 14CSunshine Biopharma Inc.SBFMWLIVE DRSSunshine Biopharma Inc.SBFMWLIVE PRE 14CSunshine Biopharma Inc.SBFMWLIVE 8-KSunshine Biopharma Inc.SBFMWLIVE 8-KSunshine Biopharma Inc.SBFMWLIVE EFFECTSunshine Biopharma Inc.SBFMWLIVE 424B3Sunshine Biopharma Inc.SBFMWLIVE S-1Sunshine Biopharma Inc.SBFMWLIVE 8-KSunshine Biopharma Inc.SBFMWLIVE SCHEDULE 13G/ASunshine Biopharma Inc.SBFMWLIVE Ownership stake disclosure by L1 Capital Global Opportunities Master Fund, Ltd. (amended)
L1 Capital Global Opportunities Master Fund, Ltd., filed by
10-QSunshine Biopharma Inc.SBFMWLIVE SCHEDULE 13G/ASunshine Biopharma Inc.SBFMWLIVE Ownership stake disclosure by INTRACOASTAL CAPITAL, LLC (amended)
INTRACOASTAL CAPITAL, LLC, filed by
4Sunshine Biopharma Inc.SBFMWLIVE David Natan, insider filing for SBFMW
David Natan, reporting
8-KSunshine Biopharma Inc.SBFMWLIVE 424B5Sunshine Biopharma Inc.SBFMWLIVE 8-KSunshine Biopharma Inc.SBFMWLIVE 8-KSunshine Biopharma Inc.SBFMWLIVE SCHEDULE 13GSunshine Biopharma Inc.SBFMWLIVE Ownership stake disclosure by Alta Partners LLC
Alta Partners LLC, filed by
DEF 14CSunshine Biopharma Inc.SBFMWLIVE PRE 14CSunshine Biopharma Inc.SBFMWLIVE 8-KSunshine Biopharma Inc.SBFMWLIVE SCHEDULE 13GSunshine Biopharma Inc.SBFMWLIVE Ownership stake disclosure by L1 Capital Global Opportunities Master Fund, Ltd.
L1 Capital Global Opportunities Master Fund, Ltd., filed by
SCHEDULE 13GSunshine Biopharma Inc.SBFMWLIVE Ownership stake disclosure by BIGGER CAPITAL FUND L P
BIGGER CAPITAL FUND L P, filed by
8-KSunshine Biopharma Inc.SBFMWLIVE 424B4Sunshine Biopharma Inc.SBFMWLIVE EFFECTSunshine Biopharma Inc.SBFMWLIVE 10-QSunshine Biopharma Inc.SBFMWLIVE S-1Sunshine Biopharma Inc.SBFMWLIVE 4Sunshine Biopharma Inc.SBFMWLIVE David Natan, insider filing for SBFMW
David Natan, reporting
8-KSunshine Biopharma Inc.SBFMWLIVE 10-KSunshine Biopharma Inc.SBFMWLIVE NT 10-KSunshine Biopharma Inc.SBFMWLIVE 8-KSunshine Biopharma Inc.SBFMWLIVE DEF 14CSunshine Biopharma Inc.SBFMWLIVE 8-KSunshine Biopharma Inc.SBFMWLIVE PRE 14CSunshine Biopharma Inc.SBFMWLIVE 8-KSunshine Biopharma Inc.SBFMWLIVE 8-KSunshine Biopharma Inc.SBFMWLIVE 10-QSunshine Biopharma Inc.SBFMWLIVE Sunshine Biopharma Inc. (SBFMW) filed its Q3 2025 quarterly report (Form 10-Q), providing investors with an update on the company's financial performance and operational activities.